CClinicalTrials.gg
Sign In
CompletedNCT02923297GALIGPARKUpdated Sep 1, 2020

GALIG Gene Expression in Parkinson's Disease

An interventional study of Blood sampling in Parkinson Disease, sponsored by Centre Hospitalier Régional d'Orléans. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2020-09-01.

Sponsored by Centre Hospitalier Régional d'Orléans · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Apr 2015, registered Oct 2016).
Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Sex
All
01

Study summary

Parkinson's disease (PD) is the most frequent neurodegenerative disorder after Alzheimer's disease. It is characterized by motor symptoms (rigidity, tremor, slowness of movements), and non-motor symptoms (neuropsychological, psychiatric, pain ...). Neuronal death initiates in the brainstem and extends progressively through the entire cortex. The processes leading to cell death are poorly understood. Pathological cells exhibit abnormal deposits, called Lewy bodies, which contain numerous proteins. A major constituent of these protein deposits is alpha-synuclein. It has recently been demonstrated, in the Laboratory of Molecular Biophysics of the CNRS (Scientific Research National Center) in Orleans, that α-synuclein interacts with Cytogaligin, a protein produced by the proapoptotic GALIG gene. Cytogaligin could thus be a factor regulating α-synuclein activity or aggregation. It is postulated that the level of expression of the GALIG gene is different in Parkinson's disease patients compared with control subjects.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • parkinson
  • alpha-synuclein
  • GALIG
  • quantitative PCR (polymerase chain reaction)
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 37 is close to the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Centre Hospitalier Régional d'Orléans is the lead sponsor of 129 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with Parkinson's Disease according to the criteria of the UKPDBB (UK Parkinson's disease brain bank).

Exclusion criteria

Exclusion Criteria:

  • Insane patient arriving without a third party.
  • Patient with Parkinson's disease arising from another etiology.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Other
    Parkinson's disease patients

    blood sampling

    Other: Blood sampling

Interventions

  • OtherBlood sampling

    blood sampling for determine and compare the expression patterns of GALIG gene

06

What researchers measure

Primary outcomes

  1. RNA (ribonucleic acid) assay of GALIG gene

    Only one assessment in the study

    Time frame: Day 0

  2. RNA (ribonucleic acid) assay of SNCA genes

    Only one assessment in the study

    Time frame: Day 0

07

Study locations

1 site
  • CHR d'ORLEANS
    Orleans, 45067, France
08

References and documents

Publications

  • Alieva AKh, Filatova EV, Karabanov AV, Illarioshkin SN, Slominsky PA, Shadrina MI. Potential Biomarkers of the Earliest Clinical Stages of Parkinson's Disease. Parkinsons Dis. 2015;2015:294396. doi: 10.1155/2015/294396. Epub 2015 Sep 21. PubMed 26483988 ↗
  • Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Goncalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltenyi G, Borovecki F, Soreq H, Ferreira JJ, F Outeiro T. Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. PLoS One. 2016 Jun 20;11(6):e0157852. doi: 10.1371/journal.pone.0157852. eCollection 2016. Erratum In: PLoS One. 2017 Dec 28;12(12):e0190552. doi: 10.1371/journal.pone.0190552. PubMed 27322389 ↗
  • Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60. doi: 10.1073/pnas.0610204104. Epub 2007 Jan 10. PubMed 17215369 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02923297
Lead sponsor
Centre Hospitalier Régional d'Orléans
Collaborators
National Scientific Research Centre
Responsible party
Sponsor
First posted
Oct 4, 2016
Start date
Apr 2015
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015
Last update
Sep 1, 2020

Study contacts

Canan OZSANCAK, Ph
principal investigator · CHR d'ORLEANS

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Parkinson Disease→

Other studies from this sponsor

Centre Hospitalier Régional d'Orléans

Start the discussion